AstraZeneca announced three agreements which are worth US$1.51 B. AstraZeneca licensed AGI-1067 in phase 3 clinical trials for treating atherosclerosis and inflammatory bowel disease from AtheroGenics which worth up to US$350 M. AstraZeneca acquired KuDOS Pharmaceuticals for total of US$210 M. AstraZeneca also signed licensing and co-development agreement for TC-1734 in phase 2 clinical trials for treating age-associated memory impairment from Targacept. The analyst opinion article states that AstraZeneca would better spend on in-licensing compounds and supporting the external biotechs through collaboration or acquisition rather than spending money on in-house R&D.